A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus

Inclusion Criteria:

- Have been treated with a stable dose of metformin for at least 3 months and have been
treated with an optimally effective and stable dose of an sulfonylurea for at least 6
months prior to screening.

- HbA1c value between 7.0% and 10.0%, inclusive.

- Body mass index (BMI) between 20 and 45 kilograms/square meter (kg/m^2), inclusive.

Exclusion Criteria:

- Known type 1 diabetes mellitus.

- More than 1 episode of severe hypoglycemia within 6 months prior to screening.

- Two or more emergency room visits or hospitalizations due to poor glucose control in
the 6 months prior to screening.

- Severe gastrointestinal disease that may significantly impact gastric emptying or
motility or having undergone gastric bypass or gastric banding surgery.

- Previous history or active diagnosis of pancreatitis.

- Positive hepatitis B surface antigen or hepatitis C antibody.

- Clinical signs or symptoms of liver disease, or hepatic aminotransferases
(aminotransferase or alanine aminotransferase) greater than 2.0× upper limit of normal
(ULN) or elevated alkaline phosphatase (greater than ULN) unrelated to bone metabolic
disease.

- Elevated total bilirubin level (greater than ULN), clinically suspicious
signs/symptoms of cirrhosis or history of cirrhosis.

- Current diagnosis, personal history of neuroendocrine tumors, family history of any
type of multiple endocrine neoplasia (MEN), or Von Hippel-Lindau.

- Contraindications for magnetic resonance imaging.